New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSelank vs Vesugen

Selank vs Vesugen

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Selank
Anti-Aging & Longevity
Vesugen
Summary
Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Half-Life
Minutes (but effects persist for hours)
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Intranasal
SubQ, Oral
Research
Typical Dose
250–500 mcg
10 mg per day
Frequency
1–3 times daily
Daily for 10–30 days
Key Benefits
  • Reduces anxiety without sedation
  • Enhances memory and learning
  • Improves focus and concentration
  • Stabilizes mood
  • Reduces physiological stress response
  • May enhance motivation
  • No addiction potential or withdrawal
  • Fast-acting — effects within 20–30 minutes
  • Approved clinically in Russia for anxiety disorders
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
Side Effects
  • Mild sedation at higher doses (paradoxical)
  • Fatigue (rare)
  • Irritability during discontinuation (uncommon)
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
Stacks With